# US 8,278,432 B2 · HBV drug resistance methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,432 B2
- Document ID: US8278432B2
- Status: Granted
- Kind: B2
- Application number: 10/509,094
- Filed: 2002-03-29
- Published: 2006-07-27
- Granted: 2012-10-02
- Earliest claimed: 2002-03-29
- Assignees: Innogenetics N.V.
- Inventors: Abdurrahman Mithat Bozdayi
- Web page: https://patentgrep.com/patent/US8278432B2

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C07K 14/005: from viruses
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12Q 1/706: {for hepatitis}
- C12N 2730/10122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

New polymorphisms in the nucleic acid sequences of the DNA polymerase/reverse transcriptase open reading frame and viral surface antigen open reading frame of the hepatitis B virus are reported. In particular, the present invention relates to the mutation YMDD→YSDD in the HBV reverse transcriptase domain and to the W196V mutation in the small HBV viral surface antigen. Said polymorphisms are affecting the detection of drug resistance mutations by genotypic methods and diagnostic kits based thereon. The present invention relates to methods and diagnostic kits for detection of a HBV virus comprising said nucleic acid polymorphisms. In particular, those methods utilizing oligonucleotides capable of hybridizing to said HBV nucleic acid polymorphisms are envisaged.

## Claims

### Claim 1

An isolated HBV polynucleic acid comprising a reverse transcriptase encoding domain, said reverse transcriptase encoding domain comprising a serine encoding codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4).

### Claim 2 (depends on 1)

The HBV polynucleic acid according to claim 1, said reverse transcriptase encoding domain further comprising a methionine encoding codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4).

### Claim 3 (depends on 1)

The HBV polynucleic acid according to claim 1 which comprises SEQ ID NO:6 or the complement thereof.

### Claim 4

An isolated HBV DNA polymerase/reverse transcriptase protein, said protein comprising a reverse transcriptase domain, said reverse transcriptase domain comprising a serine at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4).

### Claim 5 (depends on 4)

The HBV DNA polymerase/reverse transcriptase protein according to claim 4 wherein said reverse transcriptase domain further comprises a methionine at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4).

### Claim 6 (depends on 1, 2, 3)

An isolated HBV DNA polymerase/reverse transcriptase protein encoded by the isolated HBV polynucleic acid according to one of claims 1 to 3.

### Claim 7 (depends on 4)

The HBV DNA polymerase/reverse transcriptase protein according to claim 4 which comprises SEQ ID NO:4 wherein the Ser at position 108 of SEQ ID NO:4 corresponds to the serine at position 204 of the HBV reverse transcriptase domain.

### Claim 8 (depends on 1)

An isolated HBV variant comprising a polynucleic acid according to claim 1.

### Claim 9 (depends on 4)

An isolated HBV variant comprising a protein according to claim 4.

### Claim 10 (depends on 1)

A vector comprising the HBV polynucleic acid according to claim 1.

### Claim 11 (depends on 1)

An isolated host cell comprising the HBV polynucleic acid according to claim 1, a variant Hepatitis B virus containing said polynucleic acid or a vector containing said polynucleic acid.

### Claim 12 (depends on 4)

A host cell comprising the HBV DNA polymerase/reverse transcriptase protein according to claim 4 or a variant Hepatitis B virus containing said HBV DNA polymerase/reverse transcriptase protein.

### Claim 13

A method for detecting the presence of an HBV in a biological sample, said method comprising the step of detecting the presence of an HBV polynucleic acid comprising a reverse transcriptase encoding domain, said reverse transcriptase encoding domain comprising a serine encoding codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4), said method comprising:
(i) obtaining a target HBV polynucleic acid from said biological sample wherein said target HBV polynucleic acid is suspected to comprise a serine-encoding codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) or to comprise a methionine-encoding codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4) and a serine-encoding codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4);
(ii) contacting the target HBV polynucleic acid of (i) with an oligonucleotide capable of discriminating a codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4), encoding a serine from a codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4), encoding a methionine, valine or isoleucine resulting in a discriminatory signal relating to codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4), or with an oligonucleotide capable of discriminating a codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4), encoding a methionine from a codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4), encoding a leucine resulting in a discriminatory signal relating to codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4), and an oligonucleotide capable of discriminating a codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) encoding a serine from a codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) encoding a methionine, valine or isoleucine resulting in a discriminatory signal relating to codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4);
(iii) inferring, from the discriminatory signal obtained in (ii), the presence of said serine-encoding codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) or of said methionine-encoding codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4) and said serine-encoding codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) and, therefrom, the presence of said HBV in said biological sample.

### Claim 14 (depends on 13)

The method according to claim 13 wherein said discriminating in (ii) is based on hybridization and wherein said discriminatory signal in (iii) is a hybridization signal.

### Claim 15

A method for detecting resistance to lamivudine or a combination of antiviral drugs comprising lamivudine of an HBV virus present in a biological sample, said method comprising the step of detecting the presence of an HBV polynucleic acid comprising a reverse transcriptase encoding domain, said reverse transcriptase encoding domain comprising a serine encoding codon at position 204, said method comprising:
(i) obtaining a target HBV polynucleic acid from said biological sample wherein said target HBV polynucleic acid is suspected to comprise a serine-encoding codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) or to comprise a methionine-encoding codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4) and a serine-encoding codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4);
(ii) obtaining the nucleic acid sequence of the target HBV polynucleic acid of (i);
(iii) analyzing the nucleic acid sequence obtained in (ii), the presence of said serine-encoding codon at the position corresponding to position 204 of sequence P7RT or of said methionine-encoding codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4) and said serine-encoding codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) and, therefrom, said resistance to lamivudine or a combination of antiviral drugs comprising lamivudine of an HBV virus present in said biological sample.

### Claim 16

A method for detecting resistance to lamivudine or a combination of antiviral drugs comprising lamivudine of an HBV virus present in a biological sample, said method comprising the step of detecting the presence of an HBV polynucleic acid comprising a reverse transcriptase encoding domain, said reverse transcriptase encoding domain comprising a serine encoding codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4), said method comprising:
(i) obtaining a target HBV polynucleic acid from said biological sample wherein said target HBV polynucleic acid is suspected to comprise a serine-encoding codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) or to comprise a methionine-encoding codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4) and a serine-encoding codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4);
(ii) contacting the target HBV polynucleic acid of (i) with an oligonucleotide capable of discriminating a codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) encoding a serine from a codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) encoding a methionine, valine or isoleucine resulting in a discriminatory signal relating to codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4),
or with an oligonucleotide capable of discriminating a codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4) encoding a methionine from a codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4) encoding a leucine resulting in a discriminatory signal relating to codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4) and an oligonucleotide capable of discriminating a codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) encoding a serine from a codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) encoding a methionine, valine or isoleucine resulting in a discriminatory signal relating to codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4);
(iii) inferring, from the discriminatory signal obtained in (ii), the presence of said serine-encoding codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) or of said methionine-encoding codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4) and said serine-encoding codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) and, therefrom, said resistance to lamivudine or a combination of antiviral drugs comprising lamivudine of an HBV virus present in said biological sample.

### Claim 17 (depends on 16)

The method according to claim 16 wherein said discriminating in (ii) is based on hybridization and wherein said discriminatory signal in (iii) is a hybridization signal.

### Claim 18

A diagnostic kit for detecting the presence of an HBV in a biological sample comprising an oligonucleotide capable of discriminating, in said HBV polynucleic acid, a codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) encoding a serine from a codon at the position corresponding to position 204 of sequence P7RT (position 108 of SEQ ID NO:4) encoding a methionine, valine or isoleucine.

### Claim 19 (depends on 18)

The diagnostic kit according to claim 18 further comprising an oligonucleotide capable of discriminating, in said HBV polynucleic acid, a codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4) encoding a methionine from a codon at the position corresponding to position 180 of sequence P7RT (position 84 of SEQ ID NO:4) encoding a leucine.
